Baird analyst Colleen Kusy raised the firm’s price target on Enliven (ELVN) to $52 from $40 and keeps an Outperform rating on the shares. The firm updated its model as its ELVN-001 data continues to show improvement which supports its compelling profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics Announces Public Offering Agreement
- Promising Potential of Enliven Therapeutics’ ELVN-001: Buy Rating Reiterated with Strong Efficacy, Safety, and Market Opportunity
- Optimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans
- Enliven assigned with a Buy at Goldman Sachs
- Enliven Therapeutics: Promising Phase 1 Data and Strong Financial Position Support Buy Rating